drugset / Trial / NCT03636256
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation. All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma.
Timeline
- Start
- 2019-04-02
- Primary completion
- 2021-11-02
- Completion
- 2021-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NanoDoce | Unknown | 0.75 mg/ml | Other |
| Subject | NanoDoce | Unknown | 1.5 mg/ml | Other |
| Subject | NanoDoce | Unknown | 2 mg/ml | Other |
| Subject | NanoDoce | Unknown | 2.5 mg/ml | Other |
| Subject | NanoDoce | Unknown | 3 mg/ml | Other |
| Subject | NanoDoce | Unknown | 3.75 mg/ml | Other |